Driving toward targeted therapy for LCH

作者：Baiocchi Robert A^*

来源：Blood, 2014, 124(10): 1546-1548.

DOI：10.1182/blood-2014-07-587378

In this issue of Blood, Brown et al identify somatic mutations of MAP2K1 capable of driving the RAS-RAF-MEK-ERK pathway in Langerhans cell histiocytosis (LCH). Their findings lend important insight into the pathogenesis of this disease and provide the rationale for exploring targeted approaches in clinical trials.(1)

• 出版日期2014-9-4